The series A investment round secures resources for advancing global Phase I/II clinical programs and orchestrating the company’s global footprint expansion. SHANGHAI, Nov. 28, 2024 /PRNewswire/ — Allink Biotherapeutics, a clinical-stage biotechnology company pioneering next-generation…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.